Information boursière

General

Stock price

Loading…

General

Stock MarketEuronext Paris – Eurolist (compartiment B)
Reuters / BloombergTRNG.PA / TNG.FP
ISIN CodeFR0005175080
Total number of shares outstanding97,771,334
Initial Public Offering (IPO)March 26, 1998
Local Sector IndexNext Biotech / CAC Mid 100
Financial Year EndsDecember 31
Analysts
CompanyAnalystE-mailPhone
Bryan Garnier & Co. LtdJean-Jacques Le Furjjlefur@bryangarnier.com+33 (0)1 70 36 57 45
Intron HealthNaresh Chouhannaresh@intronhealthresearch.com+44 207 375 9143
Invest SecuritiesJamila El Bougrinijelbougrini@invest-securities.com+33 (0)1 44 88 88 09
Kempen & Co.Suzanne van Voorthuizensuzanne.vanvoorthuizen@kempen.com+31 (0)20 348 8484
Kepler CheuvreuxArsene Guekam Kepler’s research can be accessed hereaguekam@keplercheuvreux.com+33 1 70 81 57 56
Life Science Capital LLCJacques A. Villefrancjacques@lifesciadvisors.com+1 646 597-6997
Oddo BHFMartial Descouturesmartial.descoutures@oddo-bhf.com+33 (0)1 44 51 85 00

Any opinions, forecasts, estimates, projections or predictions regarding Transgene’s performance made by the analysts are theirs alone and do not necessarily represent the opinions, forecasts, estimates, projections or predictions of Transgene or its management. By providing the names of the analysts or certain information from them, Transgene does not imply its endorsement of or concurrence with their reports, conclusions or recommendations. Transgene assumes no liability for the accuracy of such information and undertakes no obligation to update it.

Transgene sa
400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
67405 Illkirch Graffenstaden Cedex - France |
Tel. : + 33 (0) 3 88 27 91 00

 

© 2021 Transgene - All rights reserved
Terms of use - Credits